Bu Ziying's works

Professor Bu Ziying's book Necrosis Immunotherapy for Tumors has been published by Beijing People's Military Medical Publishing House and distributed by Xinhua Bookstore, and four monographs are sold in major Xinhua Bookstores all over the country: Non-surgical Treatment of Hyperthyroidism and Thyroid Tumors, Non-surgical Treatment of Hemangiomas and Lymphangiomas, Non-surgical Treatment of Uterine Myomas and Cysts, and Non-surgical Treatment of Common Tumors. A new anti-tumor drug that is harmless to human body has obtained the national invention patent (patent number: ZL01122551.3 International patent main classification number: A6 1K33/ 14). The drug is injected directly into the tumor, killing tumor (cancer) cells without damaging normal tissues. Although tumor (cancer) cells die, necrotic tumor cells contain antigen components, which can stimulate the immune system to produce specific and non-specific antibodies, enhance the anti-tumor ability of human body, and make patients recover as soon as possible. It has no toxic and side effects of chemotherapy drugs and radiotherapy on human body, inhibits immune function, inhibits hematopoietic function of bone marrow and destroys normal tissues and cells. It is a new generation of green anti-tumor drugs and a new theory and technology. No trauma and complications caused by surgical treatment, safety, no side effects and surgical scars, so that tumor patients can recover without pain.

Over the past 20 years, more than 6,000 cases of thyroid tumor (cancer), hyperthyroidism, hysteromyoma, various cysts (including ovarian chocolate cyst), oral and facial tumors, liver cancer, lung cancer and other solid tumors, as well as hernia, hydrocele, hemorrhoids, proctoptosis and other diseases in children have been cured by non-surgical necrosis immunotherapy, which is safe and has no side effects, so that patients are exempted from the pain of surgery.

Professor Bu Ziying graduated from Anhui College of Traditional Chinese Medicine 1963 and has been engaged in medical research for more than 40 years. He has been engaged in surgical clinic and teaching. Many kinds of large cavernous hemangioma were found in clinical work, and the hemangioma could not be separated from normal tissue by surgery. Excessive resection of normal tissues, dysfunction of the affected part, local disfigurement, limb disability, high surgical risk, excessive bleeding and high incidence. Many complications have not been well solved in medical circles at home and abroad, and some serious multiple giant cavernous hemangioma can not be treated, especially the rare giant cavernous hemangioma in infants with thrombocytopenia and coagulation disorder (K-H syndrome), which brings great pain to patients and heavy ideological burden to parents.

Professor Bu Ziying thinks it is necessary to study new treatment methods and break away from conventional treatment (general conventional treatment includes surgery, laser, freezing, injection of disinfectant and injection of anti-tumor drugs). She studied a new treatment for large or severe cavernous hemangioma. After years of research, she has developed a new vaccine for treating hemangioma that is harmless to human body, and has obtained the national invention patent (patent number: ZLOH2255 1.3, special number H6 1K33/ 14). Using directional technology, drugs are directly injected into hemangioma, and drugs are used to treat hemangioma and keep powder. Has spread to the edge of hemangioma (no damage to normal tissue), directly killing blood cells in hemangioma tissue. Every time taking Chinese medicine, the phagocytosis of white blood cells increases, and white blood cells will be excreted from urine through the kidney, so that hemangioma disappears and is cured, which completely exceeds the surgical effect and is safe and has no side effects.

After years of research and clinical application, Professor Bu Ziying has cured thousands of cases of severe hemangioma and accumulated a lot of clinical experience. Non-surgical treatment of hemangioma and lymphangioma has been published by Beijing People's Military Medical Publishing House, distributed by Xinhua Bookstore, and sold by all major Xinhua bookstores in China. This monograph is a reference book for the treatment of hemangioma and lymphangioma at present, which fills the gap that there is no special treatment for hemangioma and lymphangioma at home and abroad.

There is no satisfactory treatment for hemangioma at present, and lymphangioma is more difficult to treat than hemangioma. Because of the low incidence of lymphangioma, many patients are often misdiagnosed and mistreated. At present, the main treatment is surgery. Because there is no obvious boundary between normal tissues around lymphangioma, there are many bleeding, high risks, many complications and high recurrence rate, which has always been very difficult for surgeons at home and abroad, and many large hospitals have failed to treat them well. Professor Bu Ziying used directional therapy to treat lymphangioma, which can obtain satisfactory therapeutic effect. Many patients with large-area lymphangioma who failed in surgery or other treatment methods have achieved unexpected therapeutic effects through the diagnosis and treatment of Professor Bu Ziying.